Regulatory clearances, US growth near term triggers for Lupin

India business has seen steady uptick growth over the last few quarters

Lupin’s December quarter results were a tad below expectations. Its two biggest markets, India and the US accounting for 70 per cent of the revenues, registered a growth of 5 per cent each over the year ago quarter. In a weak market, the stock was down 4 per cent. 

While the India revenues were broadly in line with expectations, the US market growth was lower than estimates. Revenue momentum in the market was impacted by the pandemic and weakness in seasonal portfolio (flu medications). Growth going ahead, however, is expected to improve driven by sharp market share gains in inhaler